68050-37-3

Basic information

• Product Name: 5-Chloroquinolin-2-aMine
• Synonyms: 5-Chloroquinolin-2-aMine
• CAS NO: 68050-37-3
• Molecular Formula: C₉H₇ClN₂
• Molecular Weight: 178.61828
• Mol File: 68050-37-3.mol

Chemical Properties

• Melting Point: 164-166 °C(Solv: dichloromethane (75-09-2); ethyl ether (60-29-7))
• Boiling Point: 340.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.363±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.54±0.50(Predicted)
• CAS DataBase Reference: 5-Chloroquinolin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloroquinolin-2-aMine(68050-37-3)
• EPA Substance Registry System: 5-Chloroquinolin-2-aMine(68050-37-3)

Safety Data

• Hazardous Substances Data: 68050-37-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloroquinolin-2-aMine is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure contributes to the development of new medications with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Chloroquinolin-2-aMine serves as an essential component in the production of agrochemicals. Its incorporation aids in the creation of effective compounds for pest control and crop protection.
Used in Organic Compounds Synthesis:
5-Chloroquinolin-2-aMine is utilized as an intermediate in the synthesis of a range of other organic compounds. Its versatile chemical properties allow for its use in the development of diverse chemical products with various applications.

Upstream product

• 769-11-9 2-chloro-6-nitroaniline 
• 107-13-1 acrylonitrile 
• 59412-12-3 2,5-dichloroquinoline 
• 23981-22-8 5-chloro-2-quinolone 
• 6361-22-4 2-chloro-6-nitrobenzaldehyde 

Relevant articles and documents

Molecular recognition via triplex formation of mixed purine/pyrimidine DNA sequences using oligoTRIPs

Stable DNA triple-helical structures are normally restricted to homopurine sequences. We have described a system of four heterocyclic bases (TRIPsides) that, when incorporated into oligomers (oligoTRIPs), can recognize and bind in the major groove to any

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Sulfonamide-containing heterocyclic compounds

The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or: (wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is ═C(D)— (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is ═C(D)—, nitrogen atom, —CH2—, oxygen atom or —CO—; Z is a single bond or —CO—NH—; and R1 is hydrogen atom, etc.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and

4H-Imidazo[2,1-c][1,4]benzoxazine-1-carboxylic acid (3) was found to possess potent activity in the IgE-induced rat passive cutaneous anaphylaxis model which may be predictive of clinical antiallergic activity. Compared to disodium cromoglycate (DSCG,1),